Abstract
X-ray crystallography is an invaluable technique in structure-based drug discovery, including fragment-based drug discovery, because it is the only technique that can provide a complete three dimensional readout of the interaction between the small molecule and its macromolecular target. X-ray diffraction (XRD) techniques can be employed as the sole method for conducting a screen of a fragment library, or it can be employed as the final technique in a screening campaign to confirm putative “hit” compounds identified by a variety of biochemical and/or biophysical screening techniques. Both approaches require an efficient technique to prepare dozens to hundreds of crystals for data collection, and a reproducible way to deliver ligands to the crystal. Here, a general method for screening cocktails of fragments is described. In cases where X-ray crystallography is employed as a method to verify putative hits, the cocktails of fragments described below would simply be replaced with single fragment solutions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041–3046
Davies TG, Tickle IJ (2012) Fragment screening by X-ray crystallography. Top Curr Chem 317:33–59
Broennimann C, Eikenberry EF, Henrich B et al (2006) The PILATUS 1 M detector. J Synchrotron Radiat 13(Pt 2):120–130
Verlinde CLMJ, Kim H, Bernstein BE et al (1997) Antitrypanosomiasis drug development based on structures of glycolytic enzymes. In: Veerapandian P (ed) Structure-based drug design. Marcel Dekker, New York, pp 365–394
Bosch J, Robien MA, Mehlin C et al (2006) Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem 49:5939–5946
Nienaber VL, Greer J (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18:1105–1108
Davies DR, Begley DW, Hartley RC et al (2011) Predicting the success of fragment screening by X-ray crystallography. Methods Enzymol 493:91–114
Davies DR, Mamat B, Magnusson OT et al (2009) Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem 52(15):4694–4715
CSGID/SSGCID (2008) X-ray crystal structure metrics for infectious disease. http://www.csgid.org/csgid/pages/sg_metrics
Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D Biol Crystallogr 60:2126–2132
Davies DR, Staker BL, Abendroth JA et al (2011) An ensemble of structures of Burkholderia pseudomallei 2,3-bisphospho-glycerate-dependent phosphoglycerate mutase. Acta Crystallogr Sect F Struct Biol Cryst Commun 67(Pt 9):1044–1050
Hassell AM, An G, Bledsoe RK et al (2007) Crystallization of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 63(Pt 1):72–79
Geremia S, Campagnolo M, Demitri N et al (2006) Simulation of diffusion time of small molecules in protein crystals. Structure 14(3):393–400
Begley DW, Hartley RC, Davies DR et al (2011) Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei. J Struct Funct Genomics 12(2):63–76
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Davies, D.R. (2014). Screening Ligands by X-ray Crystallography. In: Anderson, W.F. (eds) Structural Genomics and Drug Discovery. Methods in Molecular Biology, vol 1140. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-0354-2_23
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0354-2_23
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-0353-5
Online ISBN: 978-1-4939-0354-2
eBook Packages: Springer Protocols